CONDUIT PHARMACEUTICALS INC
Filed Sep 4, 2024.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Sep 4, 2024
Contents
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the information incorporated herein by reference contain forward-looking. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. This includes, without limitation, statements regarding the financial position and the plans and objectives of management for our future operations. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this prospectus, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus and in any document incorporated by reference in this prospectus may include, for example, statements about:
| ● | our ability to meet future capital requirements to fund our operations, which may involve debt and/or equity financing, and to obtain such debt and/or equity financing on favorable terms, and our sources and uses of cash |
| ● | the ability to maintain the listing of our securities on Nasdaq, and the potential liquidity and trading of our securities; |
| ● | the occurrence of any event, change or other circumstances, including the outcome of any legal proceedings that may be instituted against us; |
| ● | the risk of disruption to our current plans and operations; |
| ● | the ability to recognize the anticipated benefits of our business and the Business Combination (as defined below), which may be affected by, among other things, competition and the ability to grow, manage growth profitably, and retain key employees; |
| ● | costs related to our business; |
| ● | changes in applicable laws or regulations; |
| ● | our ability to execute our plans to develop and commercialize our current clinical assets, as well as any future clinical assets that we license, and the timing of any such commercialization; |
| ● | our ability to maintain existing license agreements; |
| ● | our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; |
| ● | our ability to achieve and maintain profitability in the future; |
| ● | our financial performance; and |
| ● | other factors disclosed under the section entitled “Risk Factors” in this prospectus. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.